Lantern Pharma (NASDAQ: LTRN) is set to present the growth plan for its wholly owned subsidiary, Open-Medicine AI (OMAI), during a live webinar today at 12:30 p.m. Eastern. The 45-minute session, led by CEO Panna Sharma, will cover OMAI's market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships, and contribution to shareholder value. The event will include a live demonstration of the multi-agentic AI platform followed by a question-and-answer session.
OMAI was launched as withZeta.ai in April 2026 with an initial focus on rare cancers. The platform's core capabilities and initial version were developed within Lantern's clinical programs and areas of focus. It is now expanding into additional diseases, therapy types, and stages of drug development. This expansion signals a strategic move to leverage artificial intelligence across a broader spectrum of drug discovery and development, potentially accelerating timelines and reducing costs in the pharmaceutical industry.
For those interested in viewing the full press release, it is available at https://ibn.fm/SpEDF. The latest news and updates relating to LTRN can be found in the company's newsroom at https://ibn.fm/LTRN.
Lantern Pharma is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify patients most likely to benefit from Lantern's therapies and guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
The webinar comes as AI continues to disrupt traditional drug development, offering the promise of faster, more efficient, and more personalized treatments. For investors, the update on OMAI's progress and potential partnerships could provide insight into Lantern's long-term growth prospects. The company's focus on rare cancers and expansion into other diseases highlights the versatility of its AI platform and its potential to address unmet medical needs.
AINewsWire, a specialized communications platform focused on artificial intelligence advancements, is among the 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach target markets, demographics, and industries. It also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions.
For more information, visit www.AINewsWire.com. Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer.
